Effect of preadministration of AdCMV-RAP on plasma clearance of t-PA in control and EE-treated mice. As described in Materials and Methods, EE- and vehicle-treated mice were injected with AdCMV-RAP or AdLacZ. Five days after virus administration, mice were injected with 15 μg recombinant human t-PA. Blood samples were collected at the indicated times and plasma t-PA concentrations were determined by ELISA. Data points are the mean ± SD of 3 mice in each treatment group. (○) Vehicle and AdCMV-RAP; (•) EE and AdCMV-RAP; (□) vehicle and AdLacZ; (▪) EE and AdLacZ.